You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
安圖生物(603658.SH):未來主要增長為免疫、生物、微生物、分子等板塊業務;測序與臨牀質譜今年不會上市
格隆匯 05-09 18:11

格隆匯5月9日丨安圖生物(603658.SH)於2023年4月21日召開線上交流會、2022年5月8日15:00-16:30召開2022年度暨2023年第一季度業績説明會,就“新冠疫情期間,公司並未有更多的關於新冠的收入佔比,新冠結束後,對公司的影響是否較小?一季度增長很低的原因是什麼?未來增長的主體是什麼?測序與臨牀質譜對公司的貢獻預計如何?國外的佈局進展如何?”,公司表示,2022年度公司與新冠相關收入約5億元,該業務2023年一季度明顯下降對公司業績有一定影響。未來公司主要增長為免疫、生物、微生物、分子等板塊業務;測序與臨牀質譜今年不會上市;公司將持續加大國際市場營銷力度,銷售本土化、服務本土化為後續重點工作方向。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account